STOCK TITAN

INOVIO Submits Conditional Marketing Authorization Application to European Medicines Agency for VOCERYQ™ in Adults with Recurrent Respiratory Papillomatosis

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

INOVIO (Nasdaq: INO) submitted a conditional marketing authorization application to the European Medicines Agency for VOCERYQ in adults with recurrent respiratory papillomatosis (RRP). EU marketing authorization is pending. The application includes preclinical, clinical and manufacturing data. The European Commission granted VOCERYQ orphan drug designation for RRP in 2023, and an EMA committee certified that the manufacturing and nonclinical data it reviewed met standards used to evaluate an application.

The FDA granted accelerated approval on October 30, 2026 to reduce surgery frequency in adults with RRP. Continued U.S. approval may depend on confirmation of clinical benefit. INOVIO expects U.S. orders and shipments to begin approximately 60 days after FDA approval, with a full U.S. commercial launch expected in the first quarter of 2027.

Loading...
Loading translation...
6 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointFDA accelerated approval granted October 30, 2026, to reduce surgery frequency in adults with RRP
  • Moderate pointVOCERYQ application submitted to the European Medicines Agency for conditional marketing authorization in adults with RRP
  • Moderate point. Forward-looking: it has not happened yet and may not happen.U.S. commercial rollout expected to start with orders and shipments approximately 60 days after FDA approval, followed by a full launch in the first quarter of 2027
  • Minor pointEMA committee certification confirmed that the manufacturing and nonclinical data reviewed met application evaluation standards
  • Minor pointEU orphan drug designation granted by the European Commission for RRP in 2023
  • Minor pointCELLECTRA device CE mark allows INOVIO to sell the device in the EU and other markets that recognize the mark

Negative

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Continued U.S. approval may depend on verifying and describing clinical benefit in one or more confirmatory studies
  • Minor pointEU marketing authorization for VOCERYQ remains pending
  • Minor pointU.S. label warnings cover injection-site and procedure-related reactions and advise against use on the side of an implanted defibrillator or pacemaker, or where metal implants or skin abnormalities are present at the treatment site

Key Figures

Prior close: $1.63 Pre-publication 24-hour change: +16.43%
Prior close
$1.63
Nov 17, before the EMA application announcement
Pre-publication 24-hour change
+16.43%
Market data from before the announcement

Historical Context

1 past event · Latest: Nov 10
1 event
  1. Nov 10

    FDA approval

    24h Move
    +1.7%

    FDA accelerated approval established U.S. authorization before the European marketing application.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

conditional marketing authorization, advanced therapy medicinal product (atmp) certification, chemistry, manufacturing and controls (cmc), accelerated approval
4 terms
conditional marketing authorization regulatory
"submitted a Conditional Marketing Authorization (CMA) application"
A conditional marketing authorization is a limited, temporary approval from a drug regulator that lets a medicine or vaccine be sold based on earlier or smaller amounts of safety and effectiveness data than normally required, usually because the treatment addresses a serious unmet need. It matters to investors because it can allow a company to start generating revenue sooner—like a provisional driver’s license—while carrying higher regulatory and clinical risk if follow‑up studies fail or additional data are required.
advanced therapy medicinal product (atmp) certification regulatory
"received an Advanced Therapy Medicinal Product (ATMP) Certification"
A formal scientific opinion issued by a medicines regulator (most commonly the European Medicines Agency’s Committee for Advanced Therapies) that assesses the quality and non‑clinical (preclinical) data package for an advanced therapy medicinal product—such as a gene therapy, somatic‑cell therapy or tissue‑engineered product. The certification process reviews manufacturing, characterization and preclinical study information to identify deficiencies and give developers, especially smaller companies, an official view on whether their data meet standards expected for a future marketing‑authorization application; it is not a marketing approval and does not authorize clinical use or commercialization by itself.
chemistry, manufacturing and controls (cmc) regulatory
"review of chemistry, manufacturing and controls (CMC) and nonclinical data"
Chemistry, manufacturing and controls (CMC) is the set of scientific and operational steps that show how a drug or biologic is made, what goes into it, and how its quality is consistently checked—think of it as the recipe, the factory process, and the quality checklist for a medicine. Investors care because strong CMC reduces risks around regulatory approval, production delays, batch failures and unexpected costs, directly affecting a product’s ability to reach market and generate revenue.
accelerated approval regulatory
"received FDA accelerated approval on October 30, 2026"
Accelerated approval is a process that allows new medical treatments to be approved more quickly than usual if they address serious or life-threatening conditions and show promising early results. For investors, it signals that a treatment may reach the market sooner, potentially boosting a company's prospects, but it also involves some uncertainty since full evidence of effectiveness is still being gathered.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
  • VOCERYQ™, the first FDA-approved plasmid DNA-based immunotherapy, received FDA accelerated approval on October 30, 2026
  • Recurrent Respiratory Papillomatosis (RRP) is a rare, debilitating HPV-related disease with high unmet need in Europe

PLYMOUTH MEETING, Pa., Nov. 18, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a commercial-stage biotechnology company focused on developing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has submitted a Conditional Marketing Authorization (CMA) application to the European Medicines Agency (EMA) for VOCERYQ™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), previously referred to as INO-3107, as a treatment for adults with RRP.

"Building on the recent FDA approval of VOCERYQ, we believe there's significant opportunity to transform the treatment paradigm for RRP in Europe, a region that currently has no approved non-surgical treatment options that target the root cause of RRP," said Dr. Michael Sumner, Chief Medical Officer of INOVIO. "We look forward to working closely with the EMA during the review and hope to ultimately provide RRP patients with a much-needed new treatment option that reduces the need for surgery."

"Clinicians and patients alike understand that every surgery matters, because every surgery puts a patient's vocal cords at risk," said Frederik Dikkers, Professor emeritus of Otorhinolaryngology / Head and Neck Surgery at Amsterdam University Medical Center (Amsterdam UMC). "RRP affects patients around the world, and this submission is a meaningful step forward for those in Europe who have waited far too long for relief from this debilitating disease."

The CMA application is supported by a comprehensive set of preclinical, clinical, and manufacturing data, including results from INOVIO's clinical studies for VOCERYQ published in in 2025 in Nature Communications and The Laryngoscope. An additional analysis of the data was published in October 2026 in The Laryngoscope under the title DNA Immunotherapy (INO-3107) Long-Term Efficacy Supported by Enhanced Immunogenicity in HPV-6/11 RRP.

The European Commission granted Orphan Drug designation to INO-3107, now VOCERYQ, for the treatment of RRP in 2023. INO-3107 also received an Advanced Therapy Medicinal Product (ATMP) Certification from the EMA's Committee for Advanced Therapies (CAT) after review of chemistry, manufacturing and controls (CMC) and nonclinical data. This certification confirms that the data reviewed complies with the standards that would be used to evaluate a European marketing authorization application. INOVIO submitted the marketing authorization application using guidance from pre-submission meetings with EMA and the Rapporteurs. The CELLECTRA delivery device has a CE-mark in the EU, which allows INOVIO to commercialize the device in the EU and other geographies that recognize CE-marking.

The U.S. Food and Drug Administration (FDA) granted VOCERYQ accelerated approval on October 30, 2026 for adults with RRP to reduce the frequency of surgery. Continued approval for this indication may be contingent on verification and description of clinical benefit in a confirmatory study(ies). INOVIO expects to make VOCERYQ available to order and ship in the U.S. in approximately 60 days from the date of FDA approval, with full commercial launch expected in the first quarter of 2027.

About Recurrent Respiratory Papillomatosis 
Recurrent Respiratory Papillomatosis (RRP) is a rare, debilitating disease caused primarily by HPV-6 and/or HPV-11. RRP is characterized by the development of small, wart-like growths, or papillomas, in the respiratory tract. While papillomas are generally benign, they can cause severe, life-threatening airway obstruction and respiratory complications. RRP can also significantly affect quality of life for patients by affecting the voice box, limiting the ability to speak effectively. Surgery to remove papillomas is the current standard of care for RRP; however, the papillomas often grow back. INOVIO's market research to date with patients and healthcare professionals indicates that a reduction of even one surgery matters, because every surgery poses a significant risk of causing permanent damage to the vocal cords and comes with potential costs to the patient, including adverse impacts to both quality of life and finances. Based on ongoing analysis of claims data, INOVIO believes there is a prevalent population of at least 25,000 patients with RRP in the United States, with additional patients diagnosed each year.

About VOCERYQ™
VOCERYQ is a plasmid DNA-based immunotherapy designed to reduce the frequency of surgery for adults with RRP. VOCERYQ targets the root cause of RRP by generating an immune response using DNA plasmids that encode for HPV-6 and HPV-11 antigens. VOCERYQ is administered using the CELLECTRA® 5PSP delivery device. Following a standard-of-care surgical debulking of visible papilloma prior to the initial administration of VOCERYQ, no additional surgical intervention is required as part of the 9-week dosing regimen. 

The FDA previously granted VOCERYQ both Orphan Drug and Breakthrough Therapy designations, and the European Commission granted INO-3107 Orphan Drug designation. The CELLECTRA delivery device has a CE-mark in the EU, which allows INOVIO to commercialize the device in the EU and other geographies that recognize CE-marking.

Learn more at www.voceryq.com.

INDICATION
VOCERYQ is indicated to reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis.

This indication is approved under accelerated approval based on reduction in the frequency of surgical papilloma excisions. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory study(ies).

IMPORTANT SAFETY INFORMATION 
Warnings & Precautions: Injection site reactions have occurred with VOCERYQ injection. Monitor patients for local site reactions for at least 30 minutes after treatment and manage accordingly.

Electroporation Related Adverse Reactions: Procedure-related effects including muscle contractions, transient bleeding, and vasovagal reactions may occur. Avoid use in patients with ipsilateral ICDs/pacemakers, metal implants or skin abnormalities at treatment site.

Adverse Reactions: Most common adverse reactions (incidence >5%) are injection site reactions, headache, fatigue, hypertension, nausea and dizziness.

Please go to www.voceryq.com for full Prescribing Information, including Patient Information. 

About INOVIO's DNA Medicines Platform
INOVIO's DNA medicines platform has two innovative components: precisely designed DNA plasmids, delivered by INOVIO's proprietary medical device, CELLECTRA. INOVIO uses proprietary technology to design its DNA plasmids, which are small circular DNA molecules that enable the body's cells to produce specific proteins to target and fight disease. INOVIO's proprietary CELLECTRA delivery devices are designed to optimally deliver its DNA medicines to the body's cells without requiring chemical adjuvants or lipid nanoparticles and without the risk of the anti-vector response historically seen with viral vector platforms.

About INOVIO
INOVIO is a commercial-stage biotechnology company focused on developing innovative DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of DNA medicines that enable the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com and follow us on LinkedIn and X (formerly known as Twitter).

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to our business, including the timing and success of preclinical studies and clinical studies; the ability to obtain and maintain regulatory approval of our product candidates, including in connection with our CMA application for VOCERYQ and that continued approval for VOCERYQ may be contingent on verification of clinical benefit in a confirmatory study; the potential benefits of VOCERYQ and the anticipated impact of VOCERYQ on treatment practices and outcomes for patients with RRP; the scope, progress and expansion of developing and commercializing our product candidates, including the anticipated availability and commercial launch timeline for VOCERYQ; our estimate of the prevalent population of patients with RRP in the United States; and our anticipated growth strategies. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical studies, product development programs and commercialization activities and outcomes, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured, or commercialized, that the results of clinical studies will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.

Contacts
Media: Josephine Galatioto - ICR Healthcare, inoviopr@icrhealthcare.com
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, peter.vozzo@icrhealthcare.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-submits-conditional-marketing-authorization-application-to-european-medicines-agency-for-voceryq-in-adults-with-recurrent-respiratory-papillomatosis-302943334.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did INOVIO apply for in Europe for VOCERYQ?

INOVIO applied for conditional marketing authorization from the European Medicines Agency to treat adults with recurrent respiratory papillomatosis. The application is not an approval.

When does INOVIO expect VOCERYQ to launch in the U.S.?

INOVIO expects a full U.S. commercial launch in the first quarter of 2027. The company expects VOCERYQ to be available to order and ship approximately 60 days after its October 30, 2026 FDA accelerated approval.

Which published studies support INOVIO's European application for VOCERYQ?

The application includes clinical study results published in 2025 in Nature Communications and The Laryngoscope. An additional analysis of the data appeared in The Laryngoscope in October 2026.

Does the CELLECTRA device used with INOVIO's VOCERYQ already have a European CE mark?

The CELLECTRA delivery device already has an EU CE mark, which allows INOVIO to sell the device in the EU and other markets that recognize the mark. The CE mark applies to the device, not to VOCERYQ.

Keep reading